Fuzhen Wang; Lei Cao; Keli Li; Guomin Zhang; Lixin Hao; Chao Ma; Ning Wen; Xiaoxue Liu; Jiakai Ye; Yan Li; Yudan Song; Zhijie An; Wenzhou Yu; Zundong Yin; Fuzhen Wang; Lei Cao; Keli Li; Guomin Zhang; Lixin Hao; Chao Ma; Ning Wen; Xiaoxue Liu; Jiakai Ye; Yan Li; Yudan Song; Zhijie An; Wenzhou Yu; Zundong Yin

doi:10.46234/ccdcw2025.262

[1]

Chinese Preventive Medicine Association, Vaccine and Immunization Branch, Chinese Preventive Medicine Association. Expert consensus on immunoprophylaxis of cervical cancer and other human papillomavirus-related diseases (2025 edition). Chin Prev Med 2025;26(7):775 − 812. https://doi.org/10.16506/j.1009-6639.2025.07.002.

[2]

Wei LH, Zhao C. Journey of the elimination of cervical cancer in China. Gynecol Obstet Clin Med 2024;4(3):e000052. https://doi.org/10.1136/gocm-2024-000052.

[3]

Chen H, Zhao XL, Hu SY, You TT, Xia CF, Gao M, et al. Estimation of economic burden throughout course of cervical squamous intraepithelial lesion and cervical cancer in China: a nationwide multicenter cross-sectional study. Chin J Cancer Res 2023;35(6):675 − 85. https://doi.org/10.21147/j.issn.1000-9604.2023.06.11.

[4]

Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024;74(3):229 − 63. https://doi.org/10.3322/caac.21834.

[5]

Bzhalava D, Guan P, Franceschi S, Dillner J, Clifford G. A systematic review of the prevalence of mucosal and cutaneous human papillomavirus types. Virology 2013;445(1-2):224 − 31. https://doi.org/10.1016/j.virol.2013.07.015.

[6]

Han BF, Zheng RS, Zeng HM, Wang SM, Sun KX, Chen R, et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent 2024;4(1):47 − 53. https://doi.org/10.1016/j.jncc.2024.01.006.

[7]

World Health Organization. Human papillomavirus vaccines: WHO position paper, December 2022. 2022. https://www.who.int/publications/i/item/who-wer9750-645-672. [2025-9-27].

[8]

Puthanakit T, Huang LM, Chiu CH, Tang RB, Schwarz TF, Esposito S, et al. Randomized open trial comparing 2-dose regimens of the human papillomavirus 16/18 AS04-adjuvanted vaccine in girls aged 9-14 years versus a 3-dose regimen in women aged 15-25 years. J Infect Dis 2016;214(4):525 − 36. https://doi.org/10.1093/infdis/jiw036.

[9]

Iversen OE, Miranda MJ, Ulied A, Soerdal T, Lazarus E, Chokephaibulkit K, et al. Immunogenicity of the 9-valent HPV vaccine using 2-dose regimens in girls and boys vs a 3-dose regimen in women. JAMA 2016;316(22):2411 − 21. https://doi.org/10.1001/jama.2016.17615.

[10]

Yao XM, He WG, Wu XH, Gu JX, Zhang J, Lin BZ, et al. Long-Term immunopersistence and safety of the Escherichia coli-produced HPV-16/18 bivalent vaccine in Chinese adolescent girls. Hum Vaccin Immunother 2022;18(5):2061248. https://doi.org/10.1080/21645515.2022.2061248.